Drug General Information (ID: DDIKZCL46O)
  Drug Name Heparin Drug Info Antithrombin III human Drug Info
  Drug Type Small molecule Protein/peptide
  Therapeutic Class Anticoagulants Recombinant Antithrombin

 Mechanism of Heparin-Antithrombin III human Interaction (Severity Level: Moderate)
     Increased risk of bleeding Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Heparin Antithrombin III human
      Mechanism Risk of bleeding
Anticoagulant 
Risk of bleeding
Anticoagulant 
      Key Mechanism Factor 1
Factor Name Bleeding
Factor Description Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
      Mechanism Description
  • Increased risk of bleeding by the combination of Heparin and Antithrombin III human 

Recommended Action
      Management If concomitant therapy is necessary, heparin dose reductions are recommended to avoid bleeding. Patients should be closely monitored for signs of bleeding.

References
1 Product Information. Thrombate III (antithrombin III). Bayer, West Haven, CT.